Department of Stem Cell & Regenerative Biotechnology, Konkuk University, Seoul 05029, Korea.
BMB Rep. 2019 May;52(5):295-303. doi: 10.5483/BMBRep.2019.52.5.089.
Breakthroughs in stem cell technology have contributed to disease modeling and drug screening via organoid technology. Organoid are defined as three-dimensional cellular aggregations derived from adult tissues or stem cells. They recapitulate the intricate pattern and functionality of the original tissue. Insulin is secreted mainly by the pancreatic β cells. Large-scale production of insulin-secreting β cells is crucial for diabetes therapy. Here, we provide a brief overview of organoids and focus on recent advances in protocols for the generation of pancreatic islet organoids from pancreatic tissue or pluripotent stem cells for insulin secretion. The feasibility and limitations of organoid cultures derived from stem cells for insulin production will be described. As the pancreas and gut share the same embryological origin and produce insulin, we will also discuss the possible application of gut organoids for diabetes therapy. Better understanding of the challenges associated with the current protocols for organoid culture facilitates development of scalable organoid cultures for applications in biomedicine. [BMB Reports 2019; 52(5): 295-303].
干细胞技术的突破通过类器官技术为疾病建模和药物筛选做出了贡献。类器官被定义为源自成人组织或干细胞的三维细胞聚集体。它们再现了原始组织的复杂模式和功能。胰岛素主要由胰腺β细胞分泌。大规模生产胰岛素分泌β细胞对于糖尿病治疗至关重要。在这里,我们简要概述了类器官,并重点介绍了从胰腺组织或多能干细胞生成用于胰岛素分泌的胰岛类器官的最新方案进展。将描述源自干细胞的用于胰岛素生产的类器官培养的可行性和局限性。由于胰腺和肠道具有相同的胚胎起源并产生胰岛素,我们还将讨论肠道类器官在糖尿病治疗中的可能应用。更好地了解与类器官培养相关的当前方案的挑战有助于开发可扩展的类器官培养物,以应用于生物医学。[BMB 报告 2019;52(5):295-303]。